Tags : Rituximab

Biosimilars

Samsung Biologics and AstraZeneca to Dissolve Rituximab Alliance

Shots: Samsung Biologics and AstraZeneca had decided to suspend long-running research and development activities by a jointly-owned subsidiary, Archigen Biotech, which was solely engaged in the development of SAIT101 (biosimilar, rituximab) Samsung halted the P-III study of SAIT101 in Oct’2012 and resumed it in 2014 via Archigen. The P-III study similar therapeutic effect to Rituxan […]Read More

Biosimilars Regulatory

Innovent and Lilly’s Halpryza (biosimilar, rituximab) Receive NMPA’s Approval in

Shots: NMPA has approved Halpryza for patients with DLBCL, FL, and CLL in China. The biosimilar is the fourth mAb approved in China following the approval of Tyvyt (biosimilar, sintilimab), Byvasda (biosimilar, bevacizumab) and Sulinno (biosimilar, adalimumab) The clinical efficacy and safety of rituximab in CD20 +ve NHL have been confirmed in multiple large-scale clinical […]Read More

Biosimilars

Cadila to Launch its Ritucad (rituximab, biosimilar) in India

Shots: Cadila to strengthen its biosimilar portfolio and oncology footprints in India with the launch of Ritucad and has cleared USFDA inspection in Feb’20 Additionally, the company has launched its Bevaro (bevasizumab, biosimilar) a mAb targeted for multiple cancer indications like Ovarian Cancer, Glioblastoma Multiforme (a type of Brain cancer), Colorectal Cancer, Breast Cancer, Lung […]Read More

Biosimilars Clinical Trials

Celltrion Report Results of Truxima (biosimilar, rituximab) Based Regimen in

Shots: Celltrion has presented the result of P-II study that showed that regimen of Truxima (375mg/m2) + lenalidomide (20mg, day 1-21, qd) + acalabrutinib (100mg, day 1-28, bid) (R2A) is well-tolerated and effective in relapsed/refractory aggressive B-cell lymphoma In the 13 patients who underwent disease assessment following the R2A regimen, ORR (69%) and CR (31%), […]Read More

Biosimilars

Sandoz Receives Health Canada’s Approval to Launch Ziextenzo (biosimilar, pegfilgrastim)

Shots: Health Canada has approved Ziextenzo (a biosimilar referencing Neulasta) and Riximyo (a biosimilar referencing Rituxan) for marketing in Canada Sandoz has received Health Canada’s Notice of Compliance on Apr 21, 2020, for the use of Ziextenzo to reduce the incidence of febrile neutropenia while Riximyo has received approval on Apr 28, 2020 to treat […]Read More